MEDVi
MEDVi is a telehealth company prescribing GLP-1 weight-loss medications through licensed online clinicians.
Founded
2024MEDVi is a telehealth company prescribing GLP-1 weight-loss medications through licensed online clinicians.
MEDVi runs with two employees, using AI tools for software, marketing copy, creative, and customer service, and outsources clinicians, pharmacy, shipping, and compliance to OpenLoop Health and CareValidate. eWeek reported that this structure produced a 16.2% net margin in 2025, against 5.5% for Hims & Hers, which has more than 2,400 employees.
MEDVi reported $401 million in 2025 revenue and 250,000 customers by the end of that year. Its website now claims more than 500,000 patients across its GLP-1 weight-loss, erectile dysfunction, and prepared-meal offerings.
Source:
On February 20, 2026, the FDA issued a warning letter to MEDVi, LLC finding that medvi.io presented MEDVi as the compounder of its semaglutide and tirzepatide products and implied FDA approval by comparing them with Wegovy, Ozempic, Mounjaro, and Zepbound. MEDVi attributed the site to an affiliate marketer, and the letter warned that unaddressed violations could lead to seizure or injunction.
Business Insider reported that MEDVi had been sued at least three times in 11 months over unsolicited texts and emails, and that the National Consumers League named it in a September 2025 request for an FTC investigation. Its clinical partner OpenLoop Health disclosed a January 2026 data breach affecting about 1.6 million patient records. MEDVi relies on third parties for prescribing, pharmacy fulfillment, shipping, and compliance, and the compounded GLP-1 products it markets are not FDA-approved.
Source: fda.gov
MEDVi sells through a self-serve online assessment and checkout at medvi.org, after which an OpenLoop Health clinician decides whether to prescribe. Paid social advertising is its main channel, and Gallagher told Business Insider that roughly 30% of its advertising ran through affiliate marketers.
Meta's Ad Library showed more than 5,000 active campaigns mentioning or linking to MEDVi, affiliates included, on April 3, 2026, falling to about 2,800 by April 6 after Business Insider flagged affiliate pages with apparently AI-generated doctor personas. Earned reach came mainly from the April 2, 2026 New York Times profile and the critical coverage that followed it.
Source: businessinsider.com